Lead Editor:
Professor Chih-Yang Wang,
TMU,
Taiwan
Multi-Omics and bioinformatics are widely used as systemic approaches to explore differences in expressions of thousands of genes or metabolites for both basic and clinical research. Along with medical innovation to confront the challenges that originated from mitosis in cancer, there has been continuous improvement in paradigm for diseases screening as well as more promising treatment options across disease types to significantly improve patient outcomes, relying on breakthroughs in molecular profiling and high-throughput technologies. Since characteristics of tumors and changes in metabolic pathways that occur during malignant transformation and progression can be revealed by analyzing gene expression profiles. Single-cell RNA sequencing and mass spectrometry analyses, that allow the generation of large-scale data related to multi-omics analysis (such as genomics, transcriptomics, proteomics, phenomics, and metabolomics), are widely facilitated the discovery of significant biomarkers for early diagnosis and novel therapeutic targets of drugs, followed by intercepting premalignancy. Besides that, gene therapy, defined as an approach to treat gene-related disorders by modifying faulty genes via transferring therapeutic genetic materials into the cell, is also emerging as a promising treatment therapy for rare diseases and various cancers resulting from the presence of defective genes. Although the multi-omics data from bioinformatics analysis need to be confirmed via further detailed studies, it nonetheless helps to somehow foresee the trend of information for disease to develop. However, the bioinformatics data accompanied by validation experiments are also sought after.
Submission deadline:
04/01/2026
|
Views:
